| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab169280-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
| Ab169280-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $297.90 | |
| Ab169280-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $747.90 | |
| Ab169280-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,257.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Isatuximab (anti-CD38) - Primary antibody, for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to CD38, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | 2.4.99.20 | 2'-phospho-ADP-ribosyl cyclase | 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase | 2'-phospho-cyclic-ADP-ribose transferase | ADPRC 1 | ADP-ribosyl cyclase 1 | cADPr hydrolase 1 | Cyclic ADP-ribose hydrolase 1 | EC 3.2. |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | CD38 |
| Application | ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of CD38 |
| Product Description | Isatuximab is a monoclonal antibody that targets the transmembrane receptor and the extracellular enzyme CD38, a protein highly expressed in malignant cells of the blood system, including multiple myeloma. Isatuximab has antitumor activity through a variety of biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cytophagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 extracellular enzyme activity, which is associated with many cellular functions. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 26.2 kDa (Light Chain) & 51.1 kDa (Heavy Chain), under reducing conditions; 176.8 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1461640-62-9 |
Isatuximab (anti-CD38) (Ab169280) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Isatuximab (anti-CD38) (Ab169280). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Isatuximab (anti-CD38) (Ab169280) - SEC
The purity of Isatuximab (anti-CD38) (Ab169280) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 539 |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001244 | Certificate of Analysis | Oct 10, 2023 | Ab169280 |
| ZJ23F1001245 | Certificate of Analysis | Oct 10, 2023 | Ab169280 |
| 1. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C et al.. (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.. Clin Cancer Res, 20 (17): (4574-83). [PMID:24987056] [10.1021/op500134e] |
| 2. Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML, Corzo K, Anderson KC. (2018) Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.. Future Oncol, 14 (11): (1035-1047). [PMID:29268619] [10.1021/op500134e] |
| 3. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA et al.. (2019) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.. Lancet, 394 (10214): (2096-2107). [PMID:31735560] [10.1021/op500134e] |
| 4. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al.. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.. J Immunol, 186 (3): (1840-8). [PMID:21187443] [10.1021/op500134e] |
| 5. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation.. J Immunol, 144 (7): (2811-5). [PMID:2319135] [10.1021/op500134e] |
| 6. Isabelle Kuhn,Esther Kellenberger,Fatouma Said-Hassane,Pascal Villa,Didier Rognan,Annelise Lobstein,Jacques Haiech,Marcel Hibert,Francis Schuber,Hélène Muller-Steffner. (2010-10-19) Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.. Bioorganic & medicinal chemistry, 18 ((22)): (7900-7910). [PMID:20951593] |
| 7. Swarbrick JM, Graeff R, Zhang H, Thomas MP, Hao Q, Potter BV.. (2014) Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.. J Med Chem, 57 (20): (8517-8529). [PMID:25226087] [10.1021/jm501037u] |
| 8. Jacques SA, Kuhn I, Koniev O, Schuber F, Lund FE, Wagner A, Muller-Steffner H, Kellenberger E.. (2015) Discovery of Potent Inhibitors of Schistosoma mansoni NAD⁺ Catabolizing Enzyme.. J Med Chem, 58 (8): (3582-3592). [PMID:25803425] [10.1021/acs.jmedchem.5b00203] |
| 9. Becherer JD, Boros EE, Carpenter TY, Cowan DJ, Deaton DN, Haffner CD, Jeune MR, Kaldor IW, Poole JC, Preugschat F, Rheault TR, Schulte CA, Shearer BG, Shearer TW, Shewchuk LM, Smalley TL, Stewart EL, Stuart JD, Ulrich JC.. (2015) Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.. J Med Chem, 58 (17): (7021-7056). [PMID:26267483] [10.1021/acs.jmedchem.5b00992] |
| 10. Deaton DN, Haffner CD, Henke BR, Jeune MR, Shearer BG, Stewart EL, Stuart JD, Ulrich JC.. (2018) 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships.. Bioorg Med Chem, 26 (8): (2107-2150). [PMID:29576271] [10.1016/j.bmc.2018.03.021] |
| 11. States, D J DJ, Walseth, T F TF and Lee, H C HC.. (1992) Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38.. Trends in biochemical sciences, [PMID:1471258] |
| 12. Tohgo, A A and 8 more authors.. (1994) Essential cysteine residues for cyclic ADP-ribose synthesis and hydrolysis by CD38.. The Journal of biological chemistry, (18): [PMID:7961800] |
| 13. Takasawa, S S and 7 more authors.. (1993) Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP.. The Journal of biological chemistry, (15): [PMID:8253715] |
| 14. Yagui, K K and 13 more authors.. (1998) A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro.. Diabetologia, [PMID:9754820] |
| 15. Hillman, R Tyler RT, Green, Richard E RE and Brenner, Steven E SE.. (2004) An unappreciated role for RNA surveillance.. Genome biology, [PMID:14759258] |
| 16. Liu, Qun Q and 5 more authors.. (2005) Crystal structure of human CD38 extracellular domain.. Structure (London, England : 1993), [PMID:16154090] |
| 17. Wollscheid, Bernd B and 7 more authors.. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.. Nature biotechnology, [PMID:19349973] |
| 18. Nata, K K and 9 more authors.. (1997) Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing.. Gene, (28): [PMID:9074508] |
